Other substances

RBD-16GS-I53-50

A candidate SARS-CoV-2 vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

RBD-16GS-I53-50 is a candidate vaccine. It uses the SARS-CoV-2 spike protein RBD residues 328–531 as an immunogen multivalently displayed on "I53-50" protein nanoparticle (Walls et al., 2020).

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 Spike protein Protein factor Animal model In vitro Mixed substance	BALB/c mice; Kymab Darwin mice; pigtail macaque	38.64	Elicited significantly stronger antibody (anti-spike and neutralizing) responses in mice and pigtail macaques, especially after second immunization, compared to RBD or spike trimer vaccination only.	Oct/30/2020

Export (.csv)